Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD

• Published in: Scientific reports 2019-02, Vol.9 (1), p.1910-1910, Article 1910
• Main Authors: Zhang, Hui, Xu, Hongqin, Wu, Ruihong, Yu, Ge, Sun, Haibo, Lv, Juan, Wang, Xiaomei, Chi, Xiumei, Gao, Xiuzhu, Kong, Fei, Zhang, Mingyuan, Hang, Lei, Jiang, Jing, Pan, Yu, Niu, Junqi
• Format: Article
• Language: English
• Subjects: 101/1; 13/56; 692/4020/4021/234/2513/1551; 692/699/255/234/2513/1551; Chronic infection; Creatinine; Epidermal growth factor receptors; Glomerular filtration rate; Hepatitis; Hepatitis C; Humanities and Social Sciences; Infections; Interferon; Kidney diseases; multidisciplinary; Nephropathy; Patients; Persistent infection; Renal function; Ribavirin; Risk factors; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-36437-6

Hepatitis C virus (HCV) infection greatly increases the risk of nephropathy. In this observational study, we aimed to explore the relationship between viral hepatitis infection and chronic kidney disease (CKD), identify risk factors, and determine the effect of antiviral treatment on CKD in Chinese patients with chronic HCV infection. A total of 2,435 study subjects were enrolled and divided into four groups: the HCV infection, HBV infection, HBV and HCV co-infection, and uninfected control groups. Of these, 207 patients with chronic hepatitis C (CHC) were given standard dual therapy [subcutaneous injection of recombinant interferon (IFN)-α2b and oral ribavirin (RBV)] for 48 weeks. We found that the prevalence of CKD gradually increased with age in all groups and was significantly increased in patients 60 years or older. Multivariate logistic regression analyses showed that persistent HCV infection was significantly associated with CKD [odds ratio (OR), 1.33; 95% confidence interval (CI), 1.06–1.66; P  = 0.013], whereas there was no significant link between CKD and spontaneous HCV clearance (OR, 1.23; 95% CI, 0.79–1.90; P  = 0.364), HBV infection (OR, 0.73; 95% CI, 0.44–1.19; P  = 0.201), or HBV/HCV co-infection (OR, 1.40; 95% CI, 0.81–2.40; P  = 0.234). Notably, after anti-HCV therapy, the serum creatinine concentration was significantly decreased (76.0, 75.5–79.4 μmol/L) from the pretreatment level (95.0, 93.0–97.2 μmol/L), both in patients who showed an end of treatment virological response (ETVR) and those who did not ( P